This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMedesis Pharma（76D）株式概要メデシス・ファーマS.A.はバイオ医薬品会社である。 詳細76D ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 収益が 100 万ドル未満 ( €64K )意味のある時価総額がありません ( €2M )過去5年間で収益は年間26%減少しました。 +1 さらなるリスクすべてのリスクチェックを見る76D Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.29663.2% 割高 内在価値ディスカウントEst. Revenue$PastFuture-3m429k2016201920222025202620282031Revenue €63.6kEarnings €11.6kAdvancedSet Fair ValueView all narrativesMedesis Pharma S.A. 競合他社MedigeneSymbol: XTRA:MDG1Market cap: €1.8mco.donSymbol: XTRA:CNWMarket cap: €6.5mSangui Biotech InternationalSymbol: HMSE:SBHMarket cap: €419.8kbioXXmedSymbol: DB:T5OMarket cap: €222.9k価格と性能株価の高値、安値、推移の概要Medesis Pharma過去の株価現在の株価€0.2952週高値€1.6952週安値€0.23ベータ0.181ヶ月の変化0%3ヶ月変化-12.12%1年変化-73.64%3年間の変化-91.48%5年間の変化n/aIPOからの変化-97.28%最新ニュースお知らせ • May 15Medesis Pharma S.A.(ENXTPA:ALMDP) dropped from Next Biotech IndexMedesis Pharma S.A. has been dropped from the Next Biotech Index .お知らせ • Aug 20Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024. Location: oree des mas les cypres, avenue du golf, baillargues FranceNew Risk • Jul 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€4.5m). Revenue is less than US$1m (€300k revenue, or US$327k). Market cap is less than US$10m (€4.46m market cap, or US$4.86m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€2.6m). Revenue is less than US$1m (€429k revenue, or US$463k). Market cap is less than US$10m (€5.96m market cap, or US$6.43m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).お知らせ • Apr 06Medesis Pharma Publishes an Information Note on the Three Future Drugs in Development for the Protection of Large Populations Contaminated After A Civil or Military Nuclear AccidentMedesis Pharma published an information note on the three future drugs in development for the protection of large populations contaminated after a civil or military nuclear accident. Three drugs are specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident. To date, there is no suitable treatment for a serious nuclear accident. The three products are at the heart of the issues with the tragic international situation in Ukraine, raising the possibility of nuclear war. They are also topical with the recent decisions to maintain the development of nuclear power plants. Medesis Pharma's three drug candidates were developed in collaboration with the French Atomic Energy Commission (LRT-CEA), which carried out all the studies on animals contaminated by radionuclides, and with the Armed Forces Biomedical Research Institute (IRBA) for studies on irradiated animals. Each of these products is protected by an international patent registered or in the process of being registered in most nuclear countries in the world. The therapeutic activity has been demonstrated, and a complementary program is necessary with pharmaceutical development for industrial production and a tolerance study on healthy volunteers to demonstrate safety before introducing the products into State emergency stocks. Funding requests for these 3 programs have been submitted by Medesis Pharma to the French Defense Innovation Agency. NU01: NanoCaDTPA: Plutonium decorporation: For more than 40 years, CaDTPA has been used by repeated slow IV infusion over several weeks. However, this treatment carried out in a medical environment is suitable for a few contaminated people (workers in Nuclear Power Plants), but impossible to implement when several hundred thousand people are contaminated. NanoCaDTPA (formulation of CaDTPA in the Aonys microemulsion) makes it possible to obtain the same efficiency of extraction of Plutonium, but with simple administration in the mouth, from a bottle stored at room temperature. NU02: NanoPB (Prussian Blue): Cesium decorporation: Prussian Blue has been used for many years for the extraction of Cesium. It is administered in large capsules of 500 mg, 18 capsules per day for 2 to 3 months. Impossible to dissolve, it is almost impossible to give to children and adolescents and is accompanied by obstinate constipation resulting in irradiation of the small pelvis. However, Cesium is fixed preferentially in the muscles and in particular in the heart muscle causing abnormalities and cardiac pathologies in children and adolescents. The NanoPB consists of Prussian Blue nanoparticles synthesized and stabilized in the Aonys microemulsion. It allows to obtain a decorporation of cesium 3 times faster with 100 times less Prussian Blue. It is drinkable and suitable for administration at any age, including infants and children. NP02: NanoManganese: The active ingredient is manganese sulphate in the Aonys microemulsion. This product prevents and treats the storm of inflammatory cytokines triggered by irradiation that causes major respiratory and digestive inflammation responsible for death. Efficacy is observed if treatment is started within hours of irradiation. It is administered by mouth and stored in bottles at room temperature. This product is currently in a Phase II clinical study in Brazil to treat severe forms of COVID-19 which are also linked to an inflammatory cytokine storm. Product development Plan: For each of the two decorporation products of Plutonium and Cesium: Pharmaceutical CMC development with preparation for industrial production, Tolerance study on 50 healthy volunteers treated for one month. For the radiation protection product already in clinical development: Industrial development, Tolerance study on 50 healthy volunteers for one month. Deadlines for product registration and industrial manufacturing: 18 months for the two decorporation products; 12 months for the radiation protection product. In practice, these deadlines can be shortened or extended depending on whether or not the Medicines Agency and the public authorities consider it urgent.最新情報をもっと見るRecent updatesお知らせ • May 15Medesis Pharma S.A.(ENXTPA:ALMDP) dropped from Next Biotech IndexMedesis Pharma S.A. has been dropped from the Next Biotech Index .お知らせ • Aug 20Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024. Location: oree des mas les cypres, avenue du golf, baillargues FranceNew Risk • Jul 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€4.5m). Revenue is less than US$1m (€300k revenue, or US$327k). Market cap is less than US$10m (€4.46m market cap, or US$4.86m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€2.6m). Revenue is less than US$1m (€429k revenue, or US$463k). Market cap is less than US$10m (€5.96m market cap, or US$6.43m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).お知らせ • Apr 06Medesis Pharma Publishes an Information Note on the Three Future Drugs in Development for the Protection of Large Populations Contaminated After A Civil or Military Nuclear AccidentMedesis Pharma published an information note on the three future drugs in development for the protection of large populations contaminated after a civil or military nuclear accident. Three drugs are specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident. To date, there is no suitable treatment for a serious nuclear accident. The three products are at the heart of the issues with the tragic international situation in Ukraine, raising the possibility of nuclear war. They are also topical with the recent decisions to maintain the development of nuclear power plants. Medesis Pharma's three drug candidates were developed in collaboration with the French Atomic Energy Commission (LRT-CEA), which carried out all the studies on animals contaminated by radionuclides, and with the Armed Forces Biomedical Research Institute (IRBA) for studies on irradiated animals. Each of these products is protected by an international patent registered or in the process of being registered in most nuclear countries in the world. The therapeutic activity has been demonstrated, and a complementary program is necessary with pharmaceutical development for industrial production and a tolerance study on healthy volunteers to demonstrate safety before introducing the products into State emergency stocks. Funding requests for these 3 programs have been submitted by Medesis Pharma to the French Defense Innovation Agency. NU01: NanoCaDTPA: Plutonium decorporation: For more than 40 years, CaDTPA has been used by repeated slow IV infusion over several weeks. However, this treatment carried out in a medical environment is suitable for a few contaminated people (workers in Nuclear Power Plants), but impossible to implement when several hundred thousand people are contaminated. NanoCaDTPA (formulation of CaDTPA in the Aonys microemulsion) makes it possible to obtain the same efficiency of extraction of Plutonium, but with simple administration in the mouth, from a bottle stored at room temperature. NU02: NanoPB (Prussian Blue): Cesium decorporation: Prussian Blue has been used for many years for the extraction of Cesium. It is administered in large capsules of 500 mg, 18 capsules per day for 2 to 3 months. Impossible to dissolve, it is almost impossible to give to children and adolescents and is accompanied by obstinate constipation resulting in irradiation of the small pelvis. However, Cesium is fixed preferentially in the muscles and in particular in the heart muscle causing abnormalities and cardiac pathologies in children and adolescents. The NanoPB consists of Prussian Blue nanoparticles synthesized and stabilized in the Aonys microemulsion. It allows to obtain a decorporation of cesium 3 times faster with 100 times less Prussian Blue. It is drinkable and suitable for administration at any age, including infants and children. NP02: NanoManganese: The active ingredient is manganese sulphate in the Aonys microemulsion. This product prevents and treats the storm of inflammatory cytokines triggered by irradiation that causes major respiratory and digestive inflammation responsible for death. Efficacy is observed if treatment is started within hours of irradiation. It is administered by mouth and stored in bottles at room temperature. This product is currently in a Phase II clinical study in Brazil to treat severe forms of COVID-19 which are also linked to an inflammatory cytokine storm. Product development Plan: For each of the two decorporation products of Plutonium and Cesium: Pharmaceutical CMC development with preparation for industrial production, Tolerance study on 50 healthy volunteers treated for one month. For the radiation protection product already in clinical development: Industrial development, Tolerance study on 50 healthy volunteers for one month. Deadlines for product registration and industrial manufacturing: 18 months for the two decorporation products; 12 months for the radiation protection product. In practice, these deadlines can be shortened or extended depending on whether or not the Medicines Agency and the public authorities consider it urgent.株主還元76DDE BiotechsDE 市場7D0%1.8%2.4%1Y-73.6%-12.5%1.2%株主還元を見る業界別リターン: 76D過去 1 年間で-12.5 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: 76Dは、過去 1 年間で1.2 % のリターンを上げたGerman市場を下回りました。価格変動Is 76D's price volatile compared to industry and market?76D volatility76D Average Weekly Movementn/aBiotechs Industry Average Movement8.5%Market Average Movement6.1%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.7%安定した株価: 76Dの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の76Dのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト200310Jean-Claude Maurelwww.medesispharma.comMedesis Pharma S.A.はバイオ医薬品会社として事業を展開している。同社の製品には、アルツハイマー病治療薬NanoLithium（NP03）、ハンチントン病治療薬NanosiRNA HDおよびNanoP42T、精神疾患の予防・治療薬NanoLithium、放射線防護薬NanoManganese（NP02）、核医薬品NU01プルトニウムデコレーションおよびNU02セシウムデコレーションなどがある。また、NanosiRNA IFNARやNanoManganese Radiotherapy Glioblastomaなどのがん治療薬の開発も行っている。同社は2003年に設立され、フランスのモンペリエを拠点としている。もっと見るMedesis Pharma S.A. 基礎のまとめMedesis Pharma の収益と売上を時価総額と比較するとどうか。76D 基礎統計学時価総額€1.77m収益（TTM）-€3.13m売上高(TTM)€63.64k27.8xP/Sレシオ-0.6xPER（株価収益率76D は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計76D 損益計算書（TTM）収益€63.64k売上原価€2.13m売上総利益-€2.07mその他の費用€1.07m収益-€3.13m直近の収益報告Jun 30, 2024次回決算日該当なし一株当たり利益（EPS）-0.62グロス・マージン-3,244.94%純利益率-4,924.73%有利子負債／自己資本比率-64.7%76D の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/05/15 00:11終値2025/03/11 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medesis Pharma S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 15Medesis Pharma S.A.(ENXTPA:ALMDP) dropped from Next Biotech IndexMedesis Pharma S.A. has been dropped from the Next Biotech Index .
お知らせ • Aug 20Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024. Location: oree des mas les cypres, avenue du golf, baillargues France
New Risk • Jul 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€4.5m). Revenue is less than US$1m (€300k revenue, or US$327k). Market cap is less than US$10m (€4.46m market cap, or US$4.86m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).
New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€2.6m). Revenue is less than US$1m (€429k revenue, or US$463k). Market cap is less than US$10m (€5.96m market cap, or US$6.43m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
お知らせ • Apr 06Medesis Pharma Publishes an Information Note on the Three Future Drugs in Development for the Protection of Large Populations Contaminated After A Civil or Military Nuclear AccidentMedesis Pharma published an information note on the three future drugs in development for the protection of large populations contaminated after a civil or military nuclear accident. Three drugs are specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident. To date, there is no suitable treatment for a serious nuclear accident. The three products are at the heart of the issues with the tragic international situation in Ukraine, raising the possibility of nuclear war. They are also topical with the recent decisions to maintain the development of nuclear power plants. Medesis Pharma's three drug candidates were developed in collaboration with the French Atomic Energy Commission (LRT-CEA), which carried out all the studies on animals contaminated by radionuclides, and with the Armed Forces Biomedical Research Institute (IRBA) for studies on irradiated animals. Each of these products is protected by an international patent registered or in the process of being registered in most nuclear countries in the world. The therapeutic activity has been demonstrated, and a complementary program is necessary with pharmaceutical development for industrial production and a tolerance study on healthy volunteers to demonstrate safety before introducing the products into State emergency stocks. Funding requests for these 3 programs have been submitted by Medesis Pharma to the French Defense Innovation Agency. NU01: NanoCaDTPA: Plutonium decorporation: For more than 40 years, CaDTPA has been used by repeated slow IV infusion over several weeks. However, this treatment carried out in a medical environment is suitable for a few contaminated people (workers in Nuclear Power Plants), but impossible to implement when several hundred thousand people are contaminated. NanoCaDTPA (formulation of CaDTPA in the Aonys microemulsion) makes it possible to obtain the same efficiency of extraction of Plutonium, but with simple administration in the mouth, from a bottle stored at room temperature. NU02: NanoPB (Prussian Blue): Cesium decorporation: Prussian Blue has been used for many years for the extraction of Cesium. It is administered in large capsules of 500 mg, 18 capsules per day for 2 to 3 months. Impossible to dissolve, it is almost impossible to give to children and adolescents and is accompanied by obstinate constipation resulting in irradiation of the small pelvis. However, Cesium is fixed preferentially in the muscles and in particular in the heart muscle causing abnormalities and cardiac pathologies in children and adolescents. The NanoPB consists of Prussian Blue nanoparticles synthesized and stabilized in the Aonys microemulsion. It allows to obtain a decorporation of cesium 3 times faster with 100 times less Prussian Blue. It is drinkable and suitable for administration at any age, including infants and children. NP02: NanoManganese: The active ingredient is manganese sulphate in the Aonys microemulsion. This product prevents and treats the storm of inflammatory cytokines triggered by irradiation that causes major respiratory and digestive inflammation responsible for death. Efficacy is observed if treatment is started within hours of irradiation. It is administered by mouth and stored in bottles at room temperature. This product is currently in a Phase II clinical study in Brazil to treat severe forms of COVID-19 which are also linked to an inflammatory cytokine storm. Product development Plan: For each of the two decorporation products of Plutonium and Cesium: Pharmaceutical CMC development with preparation for industrial production, Tolerance study on 50 healthy volunteers treated for one month. For the radiation protection product already in clinical development: Industrial development, Tolerance study on 50 healthy volunteers for one month. Deadlines for product registration and industrial manufacturing: 18 months for the two decorporation products; 12 months for the radiation protection product. In practice, these deadlines can be shortened or extended depending on whether or not the Medicines Agency and the public authorities consider it urgent.
お知らせ • May 15Medesis Pharma S.A.(ENXTPA:ALMDP) dropped from Next Biotech IndexMedesis Pharma S.A. has been dropped from the Next Biotech Index .
お知らせ • Aug 20Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024. Location: oree des mas les cypres, avenue du golf, baillargues France
New Risk • Jul 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€4.5m). Revenue is less than US$1m (€300k revenue, or US$327k). Market cap is less than US$10m (€4.46m market cap, or US$4.86m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).
New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€2.6m). Revenue is less than US$1m (€429k revenue, or US$463k). Market cap is less than US$10m (€5.96m market cap, or US$6.43m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
お知らせ • Apr 06Medesis Pharma Publishes an Information Note on the Three Future Drugs in Development for the Protection of Large Populations Contaminated After A Civil or Military Nuclear AccidentMedesis Pharma published an information note on the three future drugs in development for the protection of large populations contaminated after a civil or military nuclear accident. Three drugs are specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident. To date, there is no suitable treatment for a serious nuclear accident. The three products are at the heart of the issues with the tragic international situation in Ukraine, raising the possibility of nuclear war. They are also topical with the recent decisions to maintain the development of nuclear power plants. Medesis Pharma's three drug candidates were developed in collaboration with the French Atomic Energy Commission (LRT-CEA), which carried out all the studies on animals contaminated by radionuclides, and with the Armed Forces Biomedical Research Institute (IRBA) for studies on irradiated animals. Each of these products is protected by an international patent registered or in the process of being registered in most nuclear countries in the world. The therapeutic activity has been demonstrated, and a complementary program is necessary with pharmaceutical development for industrial production and a tolerance study on healthy volunteers to demonstrate safety before introducing the products into State emergency stocks. Funding requests for these 3 programs have been submitted by Medesis Pharma to the French Defense Innovation Agency. NU01: NanoCaDTPA: Plutonium decorporation: For more than 40 years, CaDTPA has been used by repeated slow IV infusion over several weeks. However, this treatment carried out in a medical environment is suitable for a few contaminated people (workers in Nuclear Power Plants), but impossible to implement when several hundred thousand people are contaminated. NanoCaDTPA (formulation of CaDTPA in the Aonys microemulsion) makes it possible to obtain the same efficiency of extraction of Plutonium, but with simple administration in the mouth, from a bottle stored at room temperature. NU02: NanoPB (Prussian Blue): Cesium decorporation: Prussian Blue has been used for many years for the extraction of Cesium. It is administered in large capsules of 500 mg, 18 capsules per day for 2 to 3 months. Impossible to dissolve, it is almost impossible to give to children and adolescents and is accompanied by obstinate constipation resulting in irradiation of the small pelvis. However, Cesium is fixed preferentially in the muscles and in particular in the heart muscle causing abnormalities and cardiac pathologies in children and adolescents. The NanoPB consists of Prussian Blue nanoparticles synthesized and stabilized in the Aonys microemulsion. It allows to obtain a decorporation of cesium 3 times faster with 100 times less Prussian Blue. It is drinkable and suitable for administration at any age, including infants and children. NP02: NanoManganese: The active ingredient is manganese sulphate in the Aonys microemulsion. This product prevents and treats the storm of inflammatory cytokines triggered by irradiation that causes major respiratory and digestive inflammation responsible for death. Efficacy is observed if treatment is started within hours of irradiation. It is administered by mouth and stored in bottles at room temperature. This product is currently in a Phase II clinical study in Brazil to treat severe forms of COVID-19 which are also linked to an inflammatory cytokine storm. Product development Plan: For each of the two decorporation products of Plutonium and Cesium: Pharmaceutical CMC development with preparation for industrial production, Tolerance study on 50 healthy volunteers treated for one month. For the radiation protection product already in clinical development: Industrial development, Tolerance study on 50 healthy volunteers for one month. Deadlines for product registration and industrial manufacturing: 18 months for the two decorporation products; 12 months for the radiation protection product. In practice, these deadlines can be shortened or extended depending on whether or not the Medicines Agency and the public authorities consider it urgent.
